Found: 28
Select item for more details and to access through your institution.
Electrophysiological Effects of a Single Intravenous Administration of Ivabradine (S 16257) in Adult Patients with Normal Baseline Electrophysiology.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 83, doi. 10.2165/00126839-200304020-00001
- By:
- Publication type:
- Article
Electrophysiological Effects of a Single Intravenous Administration of Ivabradine (S 16257) in Adult Patients with Normal Baseline Electrophysiology.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 83, doi. 10.2165/00126839-200304020-00001
- By:
- Publication type:
- Article
Electrophysiological Effects of a Single Intravenous Administration of Ivabradine (S 16257) in Adult Patients with Normal Baseline Electrophysiology.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 83, doi. 10.2165/00126839-200304020-00001
- By:
- Publication type:
- Article
Phase II Study of Antineoplaston A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma: A Preliminary Report.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 91, doi. 10.2165/00126839-200304020-00002
- By:
- Publication type:
- Article
Phase II Study of Antineoplaston A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma: A Preliminary Report.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 91, doi. 10.2165/00126839-200304020-00002
- By:
- Publication type:
- Article
Phase II Study of Antineoplaston A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma: A Preliminary Report.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 91, doi. 10.2165/00126839-200304020-00002
- By:
- Publication type:
- Article
Phase II Study of Antineoplaston A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma: A Preliminary Report.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 91, doi. 10.2165/00126839-200304020-00002
- By:
- Publication type:
- Article
Evaluation of the Antiretroviral Activity of a New Polyherbal Drug (Immu-25) in Patients with HIV Infection.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 103, doi. 10.2165/00126839-200304020-00003
- By:
- Publication type:
- Article
Evaluation of the Antiretroviral Activity of a New Polyherbal Drug (Immu-25) in Patients with HIV Infection.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 103, doi. 10.2165/00126839-200304020-00003
- By:
- Publication type:
- Article
Evaluation of the Antiretroviral Activity of a New Polyherbal Drug (Immu-25) in Patients with HIV Infection.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 103, doi. 10.2165/00126839-200304020-00003
- By:
- Publication type:
- Article
Evaluation of the Antiretroviral Activity of a New Polyherbal Drug (Immu-25) in Patients with HIV Infection.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 103, doi. 10.2165/00126839-200304020-00003
- By:
- Publication type:
- Article
Profile Summary.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 111, doi. 10.2165/00126839-200304020-00004
- Publication type:
- Article
Alpha-Antitrypsin - Alpha Therapeutic Corporation: AAT - Alpha Therapeutic Corporation, Alpha-1 Proteinase Inhibitor - Alpha Therapeutic Corporation, Alpha-1-Antitrypsin - Alpha Therapeutic Corporation, Aralast™, Respitin™.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 113, doi. 10.2165/00126839-200304020-00005
- Publication type:
- Article
Alpha-Galactosidase - Genzyme General: Fabrazyme®, Agalsidase Beta, Recombinant Human α-Galactosidase A.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 115, doi. 10.2165/00126839-200304020-00006
- Publication type:
- Article
Ambamustine: PTT119.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 119
- Publication type:
- Article
Ambamustine: PTT119.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 119
- Publication type:
- Article
Azelnidipine: CS 905, Calblock, RS 9054.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 122
- Publication type:
- Article
Azelnidipine: CS 905, Calblock, RS 9054.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 122
- Publication type:
- Article
Cyclosporin - Allergan: Ciclosporin - Allergan, Cyclosporin Ophthalmic Emulsion, Cyclosporine - Allergan, Restasis.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 126
- Publication type:
- Article
Cyclosporin - Allergan: Ciclosporin - Allergan, Cyclosporin Ophthalmic Emulsion, Cyclosporine - Allergan, Restasis.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 126
- Publication type:
- Article
Hexvix: Hexvix Pd, Hexvix Pdt.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 128
- Publication type:
- Article
Hexvix: Hexvix Pd, Hexvix Pdt.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 128
- Publication type:
- Article
Melatonin-Controlled Release - Neurim Pharmaceuticals: Circadin®, Melatonin-Prolonged Release, Melatonin-Sustained Release.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 131, doi. 10.2165/00126839-200304020-00011
- Publication type:
- Article
Melatonin-Controlled Release - Neurim Pharmaceuticals: Circadin®, Melatonin-Prolonged Release, Melatonin-Sustained Release.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 131, doi. 10.2165/00126839-200304020-00011
- Publication type:
- Article
Melatonin-Controlled Release - Neurim Pharmaceuticals: Circadin®, Melatonin-Prolonged Release, Melatonin-Sustained Release.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 131, doi. 10.2165/00126839-200304020-00011
- Publication type:
- Article
MT 300: Dihydroergotamine Mesylate Injection - POZEN.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 133
- Publication type:
- Article
MT 300: Dihydroergotamine Mesylate Injection - POZEN.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 133
- Publication type:
- Article
MT 300: Dihydroergotamine Mesylate Injection - POZEN.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 133
- Publication type:
- Article